Ohmeda's first-quarter of sales decline 9%:
This article was originally published in Clinica
Executive Summary
The BOC Group's healthcare business, Ohmeda, has seen its first-quarter sales decline 9% to £125 million ($196 million) compared with the previous year. Operating profit rose 6% to £15 million, supported by a profit on the disposal of the medical engineering systems business which supplies medical gas piping to hospitals. BOC says that during the quarter, sales of anaesthesia machines remained strong in the US while demand for equipment and devices in other markets was marginally lower than a year ago. The UK company has reported total sales for its first quarter ended December 31st, 1994, of £873.7 million, up 4%, and after-tax profit of £54.3 million compared with a loss of £34.2 million a year earlier.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.